OSAKA-GAS
3.8.2022 04:02:06 CEST | Business Wire | Press release
Daigas Gas and Power Solution Co., Ltd. (“DGPS”), a 100% subsidiary of Osaka Gas Co., Ltd. (TOKYO: 9532), has established an expanded business collaboration for onsite hydrogen generator technology with Hyundai Rotem Company (“HRC”), an affiliate of Hyundai Motor Group, allowing HRC to sell the generators outside South Korea.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220802005489/en/
Daigas Group (formerly Osaka Gas Group) launched the first model of “HYSERVE” (*1) , onsite hydrogen generator, in 2003 by adopting its accumulated knowledge on catalyst. DGPS introduced a new model “HYSERVE-300” with hourly hydrogen production capacity of 300 Nm3 in 2013. DGPS, as manufacturer of HYSERVE-300, has sold the units mainly to hydrogen fueling stations.
Then in 2019, DGPS granted HRC to manufacture and sell “Hy-Green”, hydrogen generator utilizing the technology of HYSERVE-300, enabling HRC to meet the increasing demand for hydrogen fueling stations in South Korea.
After confirming HRC’s successful launch of Hy-Green, DGPS has decided to globally deploy its HYSERVE technology through enabling HRC to sell Hy-Green outside of South Korea. DGPS believes this will contribute the prompt buildup of distributed hydrogen supply infrastructure which is necessary for the decarbonization in transportation sector.
Hy-Green will be sold by HRC for the on-site hydrogen fueling station for various hydrogen mobilities (small vehicles, buses, trucks, construction equipment, train, ships, drones and etc), fuel cell power plant, and biogas production facilities (to produce hydrogen) in order to expand the hydrogen supply chain.
HRC has already developed mass production capacity of Hy-Green and is ready for receiving inquiries from the world including those through Daigas Group.
Daigas Group including DGPS is going to expand its overseas energy business from upstream to downstream by fully utilizing its experiences in and out of Japan and its existing overseas business platforms.
(*1) |
Onsite hydrogen generator developed and sold by Daigas Group. 36 units have been sold in Japan so far. |
|
[Press Release on the launch of HYSERVE-300 (in Japanese)] |
|
https://www.osakagas.co.jp/company/press/pr_2013/1206060_7831.html |
| [Corporate Profile] | |||
| Osaka Gas Co., Ltd. | |||
Head Office: |
4-1-2 Hiranocho, Chuo-ward, Osaka-city, Osaka |
||
Representative: |
Masataka Fujiwara (President & Representative Director) |
||
Amount of Capital: |
132,166,660,000 JPY |
||
Date of Establishment: |
April 10, 1897 |
||
Business Outline: |
Natural gas distribution and supply; power generation and supply, etc. |
||
| Daigas Gas and Power Solution Co., Ltd. | |||
Head Office: |
3-5- 11 Doshomachi, Chuo-ward, Osaka-city, Osaka |
||
Representative: |
Nobushige Goto (President & Representative Director) |
||
Amount of Capital: |
100,000,000 JPY |
||
Date of Establishment: |
October 1, 2019 |
||
Business Outline: |
Operation and maintenance of gas and power plants; power generation and supply; and engineering |
||
| Hyundai Rotem Company | |||
Head Office: |
37, Cheoldobangmulgwan-ro, Uiwang-si, Gyeonggi-do, 16082, Korea |
||
Representative: |
Yong-Bae, Lee (CEO) |
||
Amount of Capital: |
545,711,465,000 KRW |
||
Date of Establishment: |
July 1, 1977 |
||
Business Outline: |
Total railway systems supply, Ground weapon systems supply, Steel, automobile production and hydrogen infrastructures supply, etc. |
||
Contact Detail: |
Duseop Lee / duseop.lee@hyundai-rotem.co.kr / +82-10-2648-5039 |
||
View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005489/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
